Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
|Articles|May 21, 2013
NOW AVAILABLE: AMCP Spring 2013 Conference Coverage
Highlights from The Academy of Managed Care Pharmacy's 25th Meeting & Expo, which took place on April 2“5, 2013, in San Diego, CA, are available in a newsletter published by The American Journal of Managed Care.
Advertisement
Highlights from The Academy of Managed Care Pharmacy's 25th Meeting & Expo, which took place on April 2—5, 2013, in San Diego, CA, are available in a newsletter published by The American Journal of Managed Care.
To access the publication, please click
Advertisement
Related to this article
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease control among 10 patients.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
340B Reform, PBM Policy Among 2027 Issues to Watch: Adam Colborn, JD
5